Across TCGA pan-cancer cohorts, SORCS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SORCS2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SORCS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SORCS2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where SORCS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.408	0.635	.001	16	view →
LUAD	OS	Quartile	II,III,IV	0.924	0.340	.005	16	view →
LSCC	OS	Quartile	III,IV	0.370	0.989	.008	14	view →
PDAC	DFS	Quartile	II,III,IV	0.224	0.463	.022	13	view →
CCRCC	OS	Quartile	All	0.486	0.930	.027	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SORCS2 tumor-vs-normal RNA expression · all SORCS2 data types